Pilar Vizcarra

List of Publications by Year
in descending order

34	687	840776 11	610901 24
papers	citations	h-index	g-index

37	37	37	1277
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV,the, 2020, 7, e554-e564.	4.7	279
2	Immune deficiency is a risk factor for severe COVIDâ€19 in people living with HIV. HIV Medicine, 2021, 22, 372-378.	2.2	123
3	Efficacy and Safety of Dolutegravir plus Boosted-Darunavir Dual Therapy among Highly Treatment-Experienced Patients. Antiviral Therapy, 2019, 24, 467-471.	1.0	20
4	Weight gain in people living with HIV switched to dual therapy. Aids, 2020, 34, 155-157.	2.2	18
5	Carbapenemase-producing Enterobacterales infections in COVID-19 patients. Infectious Diseases, 2022, 54, 36-45.	2.8	18
6	Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. HIV Research and Clinical Practice, 2019, 20, 64-72.	1.1	15
7	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. Emerging Microbes and Infections, 2021, 10, 493-496.	6.5	15
8	CD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment. International Journal of STD and AIDS, 2019, 30, 656-662.	1.1	14
9	COVID-19 and geographical area of origin. Clinical Microbiology and Infection, 2021, 27, 632.e1-632.e5.	6.0	14
10	Tâ€cell response after first dose of BNT162b2 SARSâ€CoVâ€2 vaccine among healthcare workers with previous infection or crossâ€reactive immunity. Clinical and Translational Immunology, 2021, 10, e1341.	3.8	14
11	COVID-19 in HIV-Infected Individuals: Preliminary Results of a Prospective Cohort. SSRN Electronic Journal, 0, , .	0.4	14
12	BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity. Vaccine, 2021, 39, 7367-7374.	3.8	14
13	Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis. Journal of Proteome Research, 2022, 21, 623-634.	3.7	14
14	Evaluation of kidney function in <scp>HIV</scp>â€infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Medicine, 2019, 20, 648-656.	2.2	12
15	Expansion of CD56dimCD16neg NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients. Viruses, 2022, 14, 46.	3.3	12
16	SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study. Clinical Microbiology and Infection, 2021, 27, 916.e1-916.e4.	6.0	11
17	IFNâ€Î³⁺ cell response and IFNâ€Î³ release concordance after in vitro SARSâ€CoVâ€2 stimulation. European Journal of Clinical Investigation, 2021, 51, e13636.	3.4	11
18	Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 241-245.	4.0	10

#	Article	IF	Citations
19	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S8-S19.	4.0	8
20	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2. Vaccine: X, 2022, 11, 100165.	2.1	8
21	Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2. Journal of Infection, 2022, 85, 86-89.	3.3	7
22	Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. International Journal of STD and AIDS, 2020, 31, 467-473.	1.1	5
23	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity. Frontiers in Microbiology, 2021, 12, 812729.	3.5	5
24	Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy. Infectious Diseases, 2020, 52, 202-206.	2.8	4
25	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	3.0	4
26	Implementation of a lung cancer screening initiative in HIV-infected subjects. PLoS ONE, 2021, 16, e0260069.	2.5	4
27	Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination. Journal of Clinical Medicine, 2022, 11, 3352.	2.4	3
28	SymtuzaÂ® (DRV/c/FTC/TAF) en la prÃ¡ctica clÃ¬nica. Enfermedades Infecciosas Y MicrobiologÃa ClÃ¬nica, 2018, 36, 31-36.	0.5	2
29	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. CJC Open, 2019, 1, 245-255.	1.5	2
30	Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV. HIV Research and Clinical Practice, 2020, 21, 63-71.	1.1	2
31	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. Journal of Antimicrobial Chemotherapy, 2021, 76, 1046-1050.	3.0	2
32	Progression Risk in People with HIV and COVID-19: Predictive Performance of Current Risk Scores. AIDS Research and Human Retroviruses, 2021, 37, 613-619.	1.1	2
33	Prevalencia de baja masa Ã³sea en pacientes con infecciÃ³n por VIH. Medicina ClÃ¬nica, 2021, 157, 234-237.	0.6	0
34	Prevalence of low bone mass in individuals with HIV infection. Medicina ClÃ¬nica (English Edition), 2021, 157, 234-237.	0.2	0